Abstract
Background The COVID-19 pandemic, caused by SARS-CoV-2 virus, has resulted in over 100,000 deaths in the United States. Our institution has treated over 2,000 COVID-19 patients during the pandemic in New York City. The pandemic directly impacted cancer patients and the organization of cancer care. Mount Sinai Hospital has a large and diverse multiple myeloma (MM) population. Herein, we report the characteristics of COVID-19 infection and serological response in MM patients in a large tertiary care institution in New York.
Methods We performed a retrospective study on a cohort of 58 patients with a plasma-cell disorder (54 MM, 4 smoldering MM) who developed COVID-19 between March 1, 2020 and April 30, 2020. We report epidemiological, clinical and laboratory characteristics including persistence of viral detection by polymerase chain reaction (PCR) and anti-SARS-CoV-2 antibody testing, treatments initiated, and outcomes.
Results Of the 58 patients diagnosed with COVID-19, 36 were hospitalized and 22 were managed at home. The median age was 67 years; 52% of patients were male and 63% were non-white. Hypertension (64%), hyperlipidemia (62%), obesity (37%), diabetes mellitus (28%), chronic kidney disease (24%) and lung disease (21%) were the most common comorbidities. In the total cohort, 14 patients (24%) died. Older age (>70 years), male sex, cardiovascular risk, and patients not in complete remission (CR) or stringent CR were significantly (p<0.05) associated with hospitalization. Among hospitalized patients, laboratory findings demonstrated elevation of traditional inflammatory markers (CRP, ferritin, D-dimer) and a significant (p<0.05) association between elevated inflammatory markers, severe hypogammaglobulinemia, non-white race, and mortality. Ninety-six percent (22/23) of patients developed antibodies to SARS-CoV-2 at a median of 32 days after initial diagnosis. Median time to PCR negativity was 43 (range 19-68) days from initial positive PCR.
Conclusions Drug exposure and MM disease status at the time of contracting COVID-19 had no bearing on mortality. Mounting a severe inflammatory response to SARS-CoV-2 and severe hypogammaglobulinemia were associated with higher mortality. The majority of patients mounted an antibody response to SARS-CoV-2. These findings pave a path to identification of vulnerable MM patients who need early intervention to improve outcome in future outbreaks of COVID-19.
Competing Interest Statement
Conflict of Interest: A.C.: Advisory board and consulting fees from Amgen, Antegene, Celgene, Janssen, Karyopharm, Millennium/Takeda, Novartis Pharmaceuticals, Oncopeptides, Sanofi; research funding from Amgen, Celgene, Janssen, Millennium/Takeda, Novartis Pharmaceuticals, Pharmacyclics. S. J.: Advisory board and consulting fees from Celgene, Bristol Myers Squibb, Janssen Pharmaceuticals and Merck. H. J. C: Employed by the Multiple Myeloma Research Foundation, advisory board and consulting fees from Genetech, Celgene, Bristol Myers Squibb, GlaxoSmithKline and received research funding from Takeda, Celgene,and Genetech. D. M.: Advisory board and consulting fees from Janssen, Celgene, Bristol Myers Squibb, Takeda, Legend, GlaxoSmithKline,Kinevant, and Foundation Medicine. B.W.: Consulting fees from Sanofi Genzyme. J. R.: Speaking fees from Celgene and Janssen, advisory board and consulting fees from Celgene, Janssen, Bristol Myers Squibb, Oncopeptides, Adaptive Biotechnologies, X4 Pharmaceuticals, Karyopharm, and Antegene. S. P.: Consulting fees from Foundation Medicine, research funding from Celgene and Karyopharm. Supported by 1R01CA244899-01A1. All other authors declare no potential conflict of interest.
Funding Statement
There is no outside funding declared for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This retrospective study was approved by the institutional review board (IRB) of the Mount Sinai Hospital and is in compliance with the Declaration of Helsinki and International Conference on Harmonization Guidelines for Good Clinical Practice (IRB: GCO#: 11-1433).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets analyzed during the current study are not publicly available due to United States Federal Health Insurance Portability and Accountability Act (HIPAA) compliance, but a de-identified dataset may be available from the corresponding author on reasonable request.
Abbreviations
- ACE
- angiotensin-converting-enzyme
- ALT
- alanine aminotransferase
- ARB
- angiotensin II receptor blocker
- ASCT
- autologous stem cell transplant
- AST
- aspartate aminotransferase
- BiPAP
- bi-level positive airway pressure
- BMI
- body mass index
- bpm
- beats per minute
- CAD
- coronary artery disease
- CAR
- chimeric antigen receptor
- CHF
- congestive heart failure
- CKD
- chronic kidney disease
- COPD
- chronic obstructive lung disease
- COVID-19
- coronavirus disease 2019
- CPAP
- continuous positive airway pressure
- CR
- complete response
- CRS
- cytokine release syndrome
- CRP
- C-reactive protein
- DOAC
- direct oral anticoagulant
- ECOG
- Eastern Cooperative Oncology Group
- eGFR
- estimated glomerular filtration rate
- ELISA
- enzyme-linked immunosorbent assay
- G-CSF
- granulocyte colony stimulating factor
- HIPAA
- Health Insurance Portability and Accountability Act
- IMWG
- International Myeloma Working Group
- ICU
- intensive care unit
- IL
- interleukin
- IMiD
- immunomodulatory drug
- IRB
- institutional review board
- IQR
- interquartile range
- ISS
- international staging system
- LDH
- lactate dehydrogenase
- MM
- Multiple myeloma
- OR
- odd’s ratio
- PCR
- polymerase chain reaction
- PD
- progressive disease
- PI
- proteasome inhibitor
- PR
- partial response
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus 2
- sCR
- stringent complete response
- SD
- stable disease
- SMM
- smoldering multiple myeloma
- TNF-α
- tumor necrosis factor-α
- VGPR
- very good partial response.
